Fennec Pharmaceuticals
FENC
64 hedge funds and large institutions have $101M invested in Fennec Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 26 increasing their positions, 13 reducing their positions, and 12 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 13
36% more capital invested
Capital invested by funds: $74.6M → $101M (+$26.8M)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
3.93% more ownership
Funds ownership: 54.57% → 58.51% (+3.9%)
2% more funds holding
Funds holding: 63 → 64 (+1)
8% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$6.45M |
| 2 |
SCM
Solas Capital Management
Darien,
Connecticut
|
+$1.68M |
| 3 |
Morgan Stanley
New York
|
+$1.01M |
| 4 |
CP
Clayton Partners
Berkeley,
California
|
+$208K |
| 5 |
Goldman Sachs
New York
|
+$89.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DG Capital Management
New York
|
-$2.09M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$400K |
| 3 |
WG
Winton Group
London,
United Kingdom
|
-$358K |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$304K |
| 5 |
AACP
Advantage Alpha Capital Partners
San Francisco,
California
|
-$264K |
FENC Hedge Fund Activity: Q4 2024 in Review
64 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q4 2024, worth a combined $101M — up 36% from $74.6M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new FENC positions and 12 closed out — a net gain of 1 holder — while 26 added to existing stakes and 13 trimmed.
The largest buyer was Rosalind Advisors, opening a new position worth an estimated $6.45M. The largest seller was DG Capital Management, cutting an estimated $2.09M.
- 64 institutional investors held Fennec Pharmaceuticals (FENC) as of Q4 2024, up from 63 in Q3 2024.
- Funds reported $101M of Fennec Pharmaceuticals stock for Q4 2024, up 36% quarter-over-quarter.
- 13 funds opened new Fennec Pharmaceuticals positions in Q4 2024 and 12 closed out, a net change of +1 holder.
- The largest Fennec Pharmaceuticals buyer in Q4 2024 was Rosalind Advisors, an estimated $6.45M added.
- The largest Fennec Pharmaceuticals seller in Q4 2024 was DG Capital Management, an estimated $2.09M sold.
Based on aggregated 13F filings for Q4 2024.